» Articles » PMID: 39834271

The Benefits and Harms of Oral Iron Supplementation in Non-anaemic Pregnant Women: a Systematic Review and Meta-analysis

Overview
Journal Fam Pract
Date 2025 Jan 21
PMID 39834271
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Iron deficiency during pregnancy poses a significant risk to both maternal and foetal health. Current international guidelines provide discrepant advice on antenatal iron supplementation for non-anaemic women.

Objective: We aimed to quantify the benefits and harms of routine antenatal supplementation in non-anaemic women.

Methods: The Cochrane Library, MEDLINE, Embase, and clinical trial registries were searched for randomized controlled trials and observational studies comparing oral iron supplementation with placebo or no supplement in non-anaemic pregnant women. Risk of bias was assessed for each study and the results were synthesized via meta-analysis.

Results: Twenty-three eligible studies were identified with 4492 non-anaemic pregnant women. Supplemented groups had higher haemoglobin [mean difference = 6.95 g/l, 95% confidence interval (CI): 4.81-9.09, P < .001, moderate certainty, I2 = 91%] and ferritin (mean difference = 12.22 ng/ml, 95% CI: 6.92-17.52, P < .001, moderate certainty, I2 = 87%) and were at lower risk of anaemia (relative risk = 0.50, 95% CI: 0.34-0.74, P < .001, high certainty, I2 = 42%, number needed to treat (NNT) = 10). There was no difference in birth weight, preterm birth, and rate of caesarean section. Reporting on harms was inconsistent and there was insufficient evidence to determine an association between iron supplements and any negative outcome.

Discussion: Prophylactic iron supplementation likely results in a large reduction in maternal anaemia during pregnancy. Future research should qualify the impact of this benefit on women's quality of life and determine which subpopulations benefit most. Evidence surrounding the harms of iron supplementation in the non-anaemic population is poor quality and inconsistent. Randomized controlled trials quantifying the risk of gastrointestinal (GI) disturbance and iron overload are essential to inform iron supplement use and reduce unwarranted variations in international guidelines.

References
1.
Siega-Riz A, Hartzema A, Turnbull C, Thorp J, McDonald T, Cogswell M . The effects of prophylactic iron given in prenatal supplements on iron status and birth outcomes: a randomized controlled trial. Am J Obstet Gynecol. 2006; 194(2):512-9. DOI: 10.1016/j.ajog.2005.08.011. View

2.
Pavord S, Daru J, Prasannan N, Robinson S, Stanworth S, Girling J . UK guidelines on the management of iron deficiency in pregnancy. Br J Haematol. 2019; 188(6):819-830. DOI: 10.1111/bjh.16221. View

3.
Young M, Oaks B, Rogers H, Tandon S, Martorell R, Dewey K . Maternal low and high hemoglobin concentrations and associations with adverse maternal and infant health outcomes: an updated global systematic review and meta-analysis. BMC Pregnancy Childbirth. 2023; 23(1):264. PMC: 10114461. DOI: 10.1186/s12884-023-05489-6. View

4.
Pena-Rosas J, De-Regil L, Garcia-Casal M, Dowswell T . Daily oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2015; (7):CD004736. PMC: 8918165. DOI: 10.1002/14651858.CD004736.pub5. View

5.
Nicholson W, Silverstein M, Wong J, Chelmow D, Coker T, Davis E . Screening and Supplementation for Iron Deficiency and Iron Deficiency Anemia During Pregnancy: US Preventive Services Task Force Recommendation Statement. JAMA. 2024; 332(11):906-913. DOI: 10.1001/jama.2024.15196. View